Prophylactic Anticoagulation for Catheter-related Thrombosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04256525|
Recruitment Status : Not yet recruiting
First Posted : February 5, 2020
Last Update Posted : March 26, 2020
|Condition or disease||Intervention/treatment||Phase|
|Venous Thrombosis Due to Central Venous Access Device (Disorder) Prophylactic Anticoagulation Patients With Tumor||Drug: Rivaroxaban 10mg Drug: Aspirin 100mg Drug: low molecule heparin||Phase 4|
Study Type: Interventional, randomized, parallel Assignment and no masking
Study Arms & Intervention: Drug 1: Aspirin, 100mg/day orally; Drug 2: rivaroxaban, 10mg/day orally; Drug 3: low molecule heparin, 4000IU(0.4ml)/day subcutaneous injection; Reference: mechanical prophylaxis.
Follow-up Period: 6 months. The trial visits occurred at time before each chemotherapy cycle. The following details should be included at each visit: Khorana score, height and weight, blood routine examination, coagulation function, stool-routine and occult blood test, renal and liver function, ultrasonography of both legs and neck.
Primary Outcome: The primary efficacy end point was the occurrence of thrombus in the vein at the puncture site or nearby. The primary was the occurrence of a major bleeding event as defined by the International Society on Thrombosis and Haemostasis (ISTH).
Secondary Outcome: The secondary efficacy end point was occurrence of occurrence of other thrombosis or embolism events like deep vein thrombosis or pulmonary embolism. The secondary safety endpoint was the occurrence of any clinically relevant non-major bleeding, minor bleeding and adverse events.
Population: patients with cancer and implantable venous access ports
- Age 18-75 years;
- Patients with malignant tumors who received implantable drug delivery devices as intravenous access for systematic chemotherapy;
- Eastern Cooperative Oncology Group (ECOG) class 0-1;
- Expected to receive chemotherapy within 1 week of enrollment;
- Expected survival of more than 6 months;
- Ambulatory patients or outpatient chemotherapy patients whose intravenous chemotherapy less than 24 hours per hospital stay;
- Khorana score 1-3 point.
- Patients with a history of allergies to low molecular weight heparin, rivaroxaban, aspirin or other non-steroidal anti-inflammatory drugs, especially those with asthma, neurovascular edema or shock;
- Patients with bleeding risks: thrombocytopenia (platelet count < 50*109/L), clinically significant active bleeding, active gastric ulcer disease, severe arterial hypertension, history of previous stroke;
- moderate to severe liver and kidney dysfunction;
- pregnant or lactating women;
- patients who are administered systemically with pyrrole-antimycotic agents (eg ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (eg ritonavir);
- Patients taking methotrexate;
- Patients with systemic use of non-steroidal anti-inflammatory drugs;
- Patients who have had anticoagulant drugs for any other reason.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1640 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Efficacy and Safety of Prophylactic Anticoagulation for Catheter-related Thrombosis in Patients With Cancer and Implantable Venous Access Ports: a Prospective Multi-center Randomized Controlled Trial.|
|Estimated Study Start Date :||May 1, 2020|
|Estimated Primary Completion Date :||August 30, 2021|
|Estimated Study Completion Date :||February 28, 2022|
|Experimental: Aspirin 100mg||
Drug: Aspirin 100mg
100mg orally per day
|Experimental: rivaroxaban 10mg||
Drug: Rivaroxaban 10mg
10mg orally per day
|Experimental: low molecule heparin||
Drug: low molecule heparin
0.4ml per day subcutaneous injection
No Intervention: Reference
- occurrence of catheter-related thrombosis [ Time Frame: from enrollment to the first time of occurrence of catheter-related thrombosis, up to 1 month after the completion of last chemotherapy cycle ]detect the occurrence of catheter-related thrombosis with ultrasound, venography if necessary
- occurrence of major-bleeding event [ Time Frame: from enrollment to the first time of occurrence of major-bleeding event, up to 1 month after the completion of last chemotherapy cycle ]define occurrence of major-bleeding event with ISTH standard
- occurrence of other thrombosis or embolism events except for catheter-related thrombosis [ Time Frame: from enrollment to the first time of occurrence of other thrombosis or embolism events except for catheter-related thrombosis , up to 1 month after the completion of last chemotherapy cycle ]detect deep vein thrombosis with ultrasound for the lower extremity, , ultrasound for the upper extremity, pulmonary arteriography or venography if necessary
- occurrence of clinically relevant non-major-bleeding, minor-bleeding or non-bleeding event [ Time Frame: from enrollment to the first time of occurrence of events, up to 1 month after the completion of last chemotherapy cycle ]define occurrence of non-major-bleeding or minor-bleeding event with ISTH standard, evaluate the relevant adverse drug reaction with NCI CTCAE 5.0
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04256525
|Contact: Jian Huang, Doctorfirstname.lastname@example.org|